EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo iD, Vincenzo Russo iD, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso und 4 weitere

European Journal of Clinical Investigation · 2026-01 · 56 (1)

DOI: 10.1111/eci.70132 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 10.10.2025. Verfasst von Alfredo Caturano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Insulin Resistance, Fatty Liver. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction‐associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease worldwide, driven by the increasing prevalence of obesity and insulin resistance (IR). IR, a central feature of the metabolic syndrome, promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, fostering the transition from steatosis to advanced liver injury and hepatocellular carcinoma (HCC). This review summarizes current evidence on the molecular mechanisms linking MASLD, IR and HCC, highlighting the role of insulin resistance in liver carcinogenesis and disease progression.

Methods

A comprehensive literature search was conducted to identify experimental, clinical and epidemiological studies addressing the interplay between MASLD, IR and HCC. Key molecular pathways and risk profiles were synthesised and compared across etiologies.

Results

IR contributes to hepatic lipid deposition, oxidative stress and chronic inflammation through activation of PI3K/Akt and mTOR signalling. The coexistence of MASLD and IR enhances pro‐inflammatory and pro‐fibrotic pathways, accelerating the evolution to HCC. Patients with MASLD‐associated HCC exhibit distinct metabolic and molecular characteristics compared with those with viral or alcohol‐related HCC. Novel biomarkers and advanced imaging modalities show promise for identifying high‐risk individuals at earlier disease stages.

Conclusions

Although substantial progress has been made in understanding the MASLD–IR–HCC axis, critical gaps remain regarding genetic, environmental and metabolic determinants. A multidisciplinary approach integrating metabolic, molecular and oncologic research is essential for improving early detection, risk stratification and the development of targeted therapies against metabolic liver cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsInsulin ResistanceFatty LiverMetabolic SyndromeHumansOxidative StressNon-alcoholic Fatty Liver DiseaseObesityInflammationTOR Serine-Threonine KinasesSignal Transduction

Stichwörter der Autor:innen

cancer progressionhepatocellular carcinomainsulin resistancemetabolic dysregulationmolecular pathwaystumorigenesis

Substanzen

TOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, Rome, Italy.
  • Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Data Collection G-STeP Research Core Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
  • Department of Biology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania, USA.
  • Division of Cardiology, Department of Medical Translational Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.

ORCID-Profile: Davide Nilo, Vincenzo Russo, Leonilde Bonfrate, Caterina Conte

Zitieren

APA

Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkus, E., Koudelkova, K., Cerini, F., Rizzo, A., Sasso, F. C., Bonfrate, L., Giordano, A., Yaşar, H. A., & Conte, C. (2026). Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70132

Vancouver

Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L, et al. Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70132

BibTeX
@article{Caturano2026,
  author = {Caturano, Alfredo and Erul, Enes and Nilo, Roberto and Nilo, Davide and Russo, Vincenzo and Rinaldi, Luca and Acierno, Carlo and Akkus, Erman and Koudelkova, Katerina and Cerini, Federica and Rizzo, Alessandro and Sasso, Ferdinando Carlo and Bonfrate, Leonilde and Giordano, Antonio and Yaşar, Hatime Arzu and Conte, Caterina},
  title = {Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {1},
  doi = {10.1111/eci.70132}
}
Kostenlos starten →